Coverage
-
June 03, 2013
A federal judge said Monday that Bristol-Myers Squibb Co.'s practice of subsidizing patients' drug copays didn't constitute illegal bribery, dismissing a putative class action brought by insurers that complain the payments push patients to choose brand-name drugs over cheaper generics.
1 other articles on this case.
View all »